St. Jude Medical slides on FDA order

Fri, 08/17/2012 - 10:06am
Mass Device

Shares of St. Jude Medical closed down more than 4% yesterday after the FDA ordered it to run a 3-year study of its recalled Riata defibrillator leads.

St. Jude Medical

St. Jude Medical's (NYSE:STJ) shares dropped more than 4% yesterday after the FDA ordered the medical device company to run a 3-year surveillance program of its recalled Riata defibrillator leads, plus 3 other leads that are still on the market.

STJ shares closed at $36.87 yesterday afternoon, down 4.4% on the day, but opened up slightly at $37.31 this morning. The stock has hovered around that mark so far this morning on Wall Street, reaching $36.96 as of about 10 a.m.

Yesterday afternoon the FDA ordered St. Jude to launch the 3-year post-market review of the recalled Riata and Riata ST leads, as well as for its QuickFlex LV CRT, QuickSite LV CRT, Riata ST Optim and Durata leads.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.